查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403340

到 2030 年病毒性胃肠炎市场预测：按类型、诊断、治疗、药物、剂量、适应症、给药途径、配销通路、最终用户和地区进行的全球分析

Viral Gastroenteritis Market Forecasts to 2030 - Global Analysis By Type, Diagnosis, Treatment, Drug, Dosage, Indication, Route of Administration, Distribution Channel, End User and by Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球病毒性胃肠炎市场规模为 471.6 亿美元，预计到 2030 年将达到 737.7 亿美元，预测期内复合年增长率为 6.6%。

胃肠炎，也称为病毒性胃肠炎，是一种引起肠道和胃部发炎的传染性肠道疾病。主要致病病毒为轮状病毒、腺病毒和诺罗病毒。它具有高度传染性，通常透过受污染的食物或水或与感染者的密切接触传播。常见症状包括腹泻、呕吐、腹部绞痛、发烧和噁心，严重时会导致脱水。

美国健身保健公司 Bodibio 对 33 个国家的 73,076 名成年人进行的一项调查显示，40% 的受访者患有功能性胃肠道疾病（功能性消化不良、大肠激躁症、功能性便秘）。包括所有变异）。

病毒附着传播

引起胃肠炎的病毒，如轮状病毒、诺罗病毒等，传染性极强，是造成族群感染传播的主要因素。病毒的传播主要透过人与人之间的接触、雾化呕吐物颗粒和受污染的表面进行。此外，这种传播性的增加导致病毒性胃肠炎的快速和广泛爆发，特别是在拥挤的环境和人际接触密切的社区中。

缺乏针对性的抗病毒治疗

缺乏针对包括诺罗病毒在内的许多病原体的特异性抗病毒药物，是治疗病毒性胃肠炎的主要障碍。与通常使用抗生素治疗的细菌感染不同，病毒性胃肠炎的支持治疗主要着重于保湿和缓解症状。此外，缺乏标靶抗病毒药物限制了治疗性介入的选择。

疫苗研发

研究和开发针对胃肠炎病毒（尤其是诺罗病毒）的强效疫苗的生产是一个重大机会。透过更了解宿主免疫反应和病毒基因组学，可以实现疫苗开发的新方法。此外，成功的疫苗可以彻底改变预防措施，并降低胃肠炎爆发的发生率和强度。

缺乏特异性抗病毒治疗

主要威胁之一是缺乏针对许多胃肠炎病毒的特异性抗病毒药物。病毒性胃肠炎主要透过支持性护理来治疗，治疗性介入选择有限。此外，由于缺乏针对性的抗病毒治疗，严重​​病例的治疗变得更加困难。

COVID-19 的影响：

病毒性胃肠炎市场受到了 COVID-19大流行的影响。随着全球卫生保健系统专注于控制这一流行病，病毒性胃肠炎的盛行率有所不同。为了阻止 COVID-19 的传播，人们关紧了门，保持社交距离，并改善了卫生习惯，这减少了胃肠炎病毒的传播数量。此外，由于公众对流感大流行的关注和资源的变化、监测活动的减少以及医疗服务的中断，事实证明，要准确追踪和管理胃肠炎患者很困难。

预计轮状病毒领域在预测期内将是最大的。

由于其对全球公共卫生的广泛影响，轮状病毒在病毒性胃肠炎中占据主导地位，占据最大的市场占有率。此外，众所周知，轮状病毒感染疾病是严重腹泻的主要原因，尤其是幼儿。它还显着增加了与胃肠炎相关的发病率和死亡率的整体负担。该病毒具有高度传染性，并适应多种环境，因此经常在多种环境中发现，包括儿童保育设施和医疗保健条件较差的地区。

预计门诊护理中心产业在预测期内将经历最高的复合年增长率。

复合年增长率最高的门诊护理中心产业在医疗保健产业的重要性日益增加。这些中心对于医疗保健服务的转型至关重要，因为它们专门提供门诊病人服务、诊断和预防性护理。此外，推动门诊护理成长的是向以患者为中心的模式的转变以及对负担得起且易于获得的医疗保健选择的需求不断增长。

占有率最大的地区

北美继续占据最大的市场占有率。该地区的优势可以归因于多种因素的结合，包括先进的医疗基础设施、大量的研发投资、有弹性的法规结构以及不断增长的医疗支出。而美国凭藉其先进的医疗技术、成熟的製药工业和完善的医疗保健体系，尤其成为北美医疗保健市场的主要动力。

复合年增长率最高的地区：

预计欧洲地区在预测期内复合年增长率最高。欧洲凭藉其完善的医疗基础设施、高标准的医学研究和创新以及广泛的医疗保健系统，一直在全球医疗保健市场占有很大占有率。此外，人口高龄化、慢性病发病率以及对可获得的高品质医疗保健的重视正在支持欧洲在全球医疗保健领域的持续崛起和影响力。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球病毒性胃肠炎市场：依类型

  • 诺罗病毒
  • 轮状病毒
  • 星状病毒
  • 肠腺病毒
  • 其他类型

第六章全球病毒性胃肠炎市场：依诊断

  • 体检
  • 快速粪便检验

第七章全球病毒性胃肠炎市场：依治疗分类

  • 静脉输液
  • 运动抑制剂
  • 电解质
  • 止吐药
  • 止泻药
  • 其他治疗

第八章全球病毒性胃肠炎市场：依药物分类

  • 抗生素
  • 抗酸剂
  • 泻药
  • 化疗药物
  • 其他药品

第九章全球病毒性胃肠炎市场：依药物分类

  • 锭剂
  • 注射
  • 其他药物

第十章全球病毒性胃肠炎市场：依适应症分类

  • 水样腹泻
  • 呕吐
  • 腹痛和痉挛
  • 晕眩的
  • 腹泻
  • 噁心
  • 呕吐
  • 头痛
  • 寒冷的
  • 食慾下降
  • 热
  • 关节僵硬
  • 流汗
  • 肌肉疼痛
  • 减重
  • 其他适应症

第十一章全球病毒性胃肠炎市场：依给药途径

  • 口服
  • 静脉
  • 其他的

第十二章全球病毒性胃肠炎市场：按配销通路

  • 医院药房
  • 零售药房
  • 线上药房

第十三章全球病毒性胃肠炎市场：依最终用户分类

  • 诊断中心
  • 门诊治疗中心
  • 其他最终用户

第十四章全球病毒性胃肠炎市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十五章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十六章 公司简介

  • Bausch Health Companies Inc.
  • Abbott
  • Cipla Inc.
  • Sanofi
  • Bayer AG
  • Allergan
  • Dr. Reddy's Laboratories Ltd.
  • Johnson & Johnson Private Ltd.
  • Takeda Pharmaceutical Company Ltd.
  • Valeant Pharmaceuticals
  • Astellas Pharma Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma
  • Eli Lilly and Company
  • Novartis AG
  • Janssen Biotech Inc.
  • Mylan NV
Product Code: SMRC24565

According to Stratistics MRC, the Global Viral Gastroenteritis Market is accounted for $47.16 billion in 2023 and is expected to reach $73.77 billion by 2030 growing at a CAGR of 6.6% during the forecast period. The stomach flu, also referred to as viral gastroenteritis, is an infectious intestinal disease that causes inflammation in the intestines and stomach. The rotavirus, adenovirus, and norovirus are the main viruses that cause it. Being highly contagious, the illness usually spreads through contaminated food, water, or intimate contact with an infected person. Moreover, diarrhea, vomiting, cramps in the abdomen, fever, and nausea are common symptoms; in severe cases, dehydration results.

According to a survey report across 33 countries among 73,076 adults by Bodibio, a US-based fitness and wellness company, 40% of those surveyed had a functional gastrointestinal disorder, including all the variations of functional dyspepsia, irritable bowel syndrome, functional constipation, and others.

Market Dynamics:

Driver:

Spread of viral adherence

The highly contagious nature of viruses that cause gastroenteritis, like rotavirus and norovirus, is a major factor in the spread of outbreaks. Viral transmission occurs mainly through person-to-person contact, aerosolized vomit particles, and contaminated surfaces. Additionally, this increased transmissibility, particularly in crowded environments and communities with close interpersonal contact, plays a role in the quick and widespread occurrence of viral gastroenteritis.

Restraint:

Lack of targeted antiviral treatment

The lack of specific antiviral drugs for many of the causative agents, including norovirus, is a significant barrier to treating viral gastroenteritis. In contrast to bacterial infections, which are typically treated with antibiotics, supportive care for viral gastroenteritis primarily focuses on rehydration and symptom relief. Furthermore, therapeutic intervention options are limited due to the absence of targeted antiviral drugs.

Opportunity:

Development and research on vaccines

Research and development efforts aimed at producing potent vaccines against gastroenteritis viruses, particularly noroviruses, present a substantial opportunity. Novel approaches to the development of vaccines could be made possible by growing comprehension of host immune responses and viral genomics. Moreover, a successful vaccine could transform prophylactic measures and lessen the incidence and intensity of gastroenteritis outbreaks.

Threat:

Absence of particularized antiviral therapy

One major threat is the lack of specific antiviral drugs for many gastroenteritis viruses. Viral gastroenteritis is primarily treated with supportive care, with limited options for therapeutic interventions, unlike bacterial infections, which are frequently treated with targeted antibiotics. Additionally, the management of severe cases is made more difficult by the absence of a targeted antiviral treatment.

COVID-19 Impact:

The market for viral gastroenteritis has been affected by the COVID-19 pandemic. As global healthcare systems have primarily concentrated on controlling the pandemic, there have been variations in the prevalence of viral gastroenteritis cases. In an attempt to stop the spread of COVID-19, lockdowns, social distancing measures, and improved hygiene practices have all somewhat reduced the number of gastroenteritis viruses that are being transmitted. Moreover, accurately tracking and managing gastroenteritis cases has proven difficult, due to changes in public attention and resources towards the pandemic, decreased surveillance efforts, and disruptions in healthcare services.

The Rotavirus segment is expected to be the largest during the forecast period

Due to the widespread influence on public health worldwide, the rotavirus segment is a dominant force in the viral gastroenteritis landscape, possessing the largest market share. Additionally, rotavirus infections are well known for being a major cause of severe diarrhea, particularly in young children. They also significantly increase the overall burden of morbidity and mortality associated with gastroenteritis. Due to the virus's high contagiousness and adaptability to different environments, it is frequently found in a wide range of settings, including childcare facilities and areas with poor access to healthcare.

The Ambulatory Care Centers segment is expected to have the highest CAGR during the forecast period

With the highest CAGR, the ambulatory care center segment is becoming more and more important in the healthcare sector. These centers are essential to the transformation of healthcare delivery because they are dedicated to providing outpatient services, diagnostics, and preventive care. Furthermore, the growth of ambulatory care has been driven by a shift towards patient-centric models and an increasing demand for affordable and easily accessible healthcare options.

Region with largest share:

North America has continuously held the largest market share. The region's prominence is ascribed to a confluence of factors such as sophisticated healthcare infrastructure, significant investments in research and development, a resilient regulatory framework, and elevated healthcare spending. However, with its sophisticated medical technology, firmly established pharmaceutical industry, and extensive healthcare system, the United States in particular stands out as a major driver of the North American healthcare market.

Region with highest CAGR:

During the forecast period, the European region is expected to have the highest CAGR. Europe consistently holds a sizable share of the global healthcare market thanks to its well-established healthcare infrastructure, high standards for medical research and innovation, and extensive healthcare systems. Moreover, the aging population, the frequency of chronic illnesses, and the emphasis on accessible and high-quality healthcare all support Europe's continued rise and clout in the world healthcare arena.

Key players in the market:

Some of the key players in Viral Gastroenteritis market include Bausch Health Companies Inc., Abbott, Cipla Inc., Sanofi, Bayer AG, Allerga, Dr. Reddy's Laboratories Ltd, Johnson & Johnson Private Ltd., Takeda Pharmaceutical Company Ltd., Valeant Pharmaceuticals, Astellas Pharma Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Eli Lilly and Company, Novartis AG, Janssen Biotech Inc. and Mylan N.V.

Key Developments:

In September 2023, Bausch + Lomb Corporation, a subsidiary of Bausch Health Companies Inc., announced it has completed its acquisition of XIIDRA® 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye, and certain other ophthalmology assets.

In September 2023, Abbott has entered a definitive agreement for the acquisition of Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes. Together, the companies have worked on connected diabetes solutions since 2017. Developed by Bigfoot Biomedical, Bigfoot Unity is a smart insulin management system. It features connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data and healthcare provider instructions.

In April 2023, Cipla has signed a perpetual license agreement with Switzerland-based Novartis Pharma AG to manufacture and market Galvus and Galvus combination brands which are used in the treatment of type 2 diabetes from January 1, 2026.

Types Covered:

  • Norovirus
  • Rotavirus
  • Astrovirus
  • Enteric Adenovirus
  • Other Types

Diagnosis's Covered:

  • Physical Examination
  • Rapid Stool Test

Treatments Covered:

  • Intravenous Fluids
  • Antimotility Agents
  • Electrolytes
  • Antiemetic Drugs
  • Antidiarrheal Drugs
  • Other Treatments

Drugs Covered:

  • Antibiotics
  • Antacids
  • Laxatives
  • Chemotherapy Drugs
  • Other Drugs

Dosages Covered:

  • Tablet
  • Injection
  • Other Dosages

Indications Covered:

  • Watery Diarrhea
  • Vomiting
  • Abdominal Pain and Cramps
  • Dizziness
  • Diarrhea
  • Nausea
  • Vomiting
  • Headache
  • Chills
  • Loss of Appetite
  • Fever
  • Joint Stiffness
  • Sweating
  • Muscle Pain
  • Weight Loss
  • Other Indications

Route of Administrations Covered:

  • Oral
  • Intravenous
  • Others

Distribution Channels Covered:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

End Users Covered:

  • Diagnostic Centers
  • Ambulatory Care Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Viral Gastroenteritis Market, By Type

  • 5.1 Introduction
  • 5.2 Norovirus
  • 5.3 Rotavirus
  • 5.4 Astrovirus
  • 5.5 Enteric Adenovirus
  • 5.6 Other Types

6 Global Viral Gastroenteritis Market, By Diagnosis

  • 6.1 Introduction
  • 6.2 Physical Examination
  • 6.3 Rapid Stool Test

7 Global Viral Gastroenteritis Market, By Treatment

  • 7.1 Introduction
  • 7.2 Intravenous Fluids
  • 7.3 Antimotility Agents
  • 7.4 Electrolytes
  • 7.5 Antiemetic Drugs
  • 7.6 Antidiarrheal Drugs
  • 7.7 Other Treatments

8 Global Viral Gastroenteritis Market, By Drug

  • 8.1 Introduction
  • 8.2 Antibiotics
  • 8.3 Antacids
  • 8.4 Laxatives
  • 8.5 Chemotherapy Drugs
  • 8.6 Other Drugs

9 Global Viral Gastroenteritis Market, By Dosage

  • 9.1 Introduction
  • 9.2 Tablet
  • 9.3 Injection
  • 9.4 Other Dosages

10 Global Viral Gastroenteritis Market, By Indication

  • 10.1 Introduction
  • 10.2 Watery Diarrhea
  • 10.3 Vomiting
  • 10.4 Abdominal Pain and Cramps
  • 10.5 Dizziness
  • 10.6 Diarrhea
  • 10.7 Nausea
  • 10.8 Vomiting
  • 10.9 Headache
  • 10.10 Chills
  • 10.11 Loss of Appetite
  • 10.12 Fever
  • 10.13 Joint Stiffness
  • 10.14 Sweating
  • 10.15 Muscle Pain
  • 10.16 Weight Loss
  • 10.17 Other Indications

11 Global Viral Gastroenteritis Market, By Route of Administration

  • 11.1 Introduction
  • 11.2 Oral
  • 11.3 Intravenous
  • 11.4 Others

12 Global Viral Gastroenteritis Market, By Distribution Channel

  • 12.1 Introduction
  • 12.2 Hospital Pharmacy
  • 12.3 Retail Pharmacy
  • 12.4 Online Pharmacy

13 Global Viral Gastroenteritis Market, By End User

  • 13.1 Introduction
  • 13.2 Diagnostic Centers
  • 13.3 Ambulatory Care Centers
  • 13.4 Other End Users

14 Global Viral Gastroenteritis Market, By Geography

  • 14.1 Introduction
  • 14.2 North America
    • 14.2.1 US
    • 14.2.2 Canada
    • 14.2.3 Mexico
  • 14.3 Europe
    • 14.3.1 Germany
    • 14.3.2 UK
    • 14.3.3 Italy
    • 14.3.4 France
    • 14.3.5 Spain
    • 14.3.6 Rest of Europe
  • 14.4 Asia Pacific
    • 14.4.1 Japan
    • 14.4.2 China
    • 14.4.3 India
    • 14.4.4 Australia
    • 14.4.5 New Zealand
    • 14.4.6 South Korea
    • 14.4.7 Rest of Asia Pacific
  • 14.5 South America
    • 14.5.1 Argentina
    • 14.5.2 Brazil
    • 14.5.3 Chile
    • 14.5.4 Rest of South America
  • 14.6 Middle East & Africa
    • 14.6.1 Saudi Arabia
    • 14.6.2 UAE
    • 14.6.3 Qatar
    • 14.6.4 South Africa
    • 14.6.5 Rest of Middle East & Africa

15 Key Developments

  • 15.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 15.2 Acquisitions & Mergers
  • 15.3 New Product Launch
  • 15.4 Expansions
  • 15.5 Other Key Strategies

16 Company Profiling

  • 16.1 Bausch Health Companies Inc.
  • 16.2 Abbott
  • 16.3 Cipla Inc.
  • 16.4 Sanofi
  • 16.5 Bayer AG
  • 16.6 Allergan
  • 16.7 Dr. Reddy's Laboratories Ltd.
  • 16.8 Johnson & Johnson Private Ltd.
  • 16.9 Takeda Pharmaceutical Company Ltd.
  • 16.10 Valeant Pharmaceuticals
  • 16.11 Astellas Pharma Inc.
  • 16.12 Teva Pharmaceutical Industries Ltd.
  • 16.13 Sun Pharmaceutical Industries Ltd.
  • 16.14 Aurobindo Pharma
  • 16.15 Eli Lilly and Company
  • 16.16 Novartis AG
  • 16.17 Janssen Biotech Inc.
  • 16.18 Mylan N.V.

List of Tables

  • Table 1 Global Viral Gastroenteritis Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Viral Gastroenteritis Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Viral Gastroenteritis Market Outlook, By Norovirus (2021-2030) ($MN)
  • Table 4 Global Viral Gastroenteritis Market Outlook, By Rotavirus (2021-2030) ($MN)
  • Table 5 Global Viral Gastroenteritis Market Outlook, By Astrovirus (2021-2030) ($MN)
  • Table 6 Global Viral Gastroenteritis Market Outlook, By Enteric Adenovirus (2021-2030) ($MN)
  • Table 7 Global Viral Gastroenteritis Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 8 Global Viral Gastroenteritis Market Outlook, By Diagnosis (2021-2030) ($MN)
  • Table 9 Global Viral Gastroenteritis Market Outlook, By Physical Examination (2021-2030) ($MN)
  • Table 10 Global Viral Gastroenteritis Market Outlook, By Rapid Stool Test (2021-2030) ($MN)
  • Table 11 Global Viral Gastroenteritis Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 12 Global Viral Gastroenteritis Market Outlook, By Intravenous Fluids (2021-2030) ($MN)
  • Table 13 Global Viral Gastroenteritis Market Outlook, By Antimotility Agents (2021-2030) ($MN)
  • Table 14 Global Viral Gastroenteritis Market Outlook, By Electrolytes (2021-2030) ($MN)
  • Table 15 Global Viral Gastroenteritis Market Outlook, By Antiemetic Drugs (2021-2030) ($MN)
  • Table 16 Global Viral Gastroenteritis Market Outlook, By Antidiarrheal Drugs (2021-2030) ($MN)
  • Table 17 Global Viral Gastroenteritis Market Outlook, By Other Treatments (2021-2030) ($MN)
  • Table 18 Global Viral Gastroenteritis Market Outlook, By Drug (2021-2030) ($MN)
  • Table 19 Global Viral Gastroenteritis Market Outlook, By Antibiotics (2021-2030) ($MN)
  • Table 20 Global Viral Gastroenteritis Market Outlook, By Antacids (2021-2030) ($MN)
  • Table 21 Global Viral Gastroenteritis Market Outlook, By Laxatives (2021-2030) ($MN)
  • Table 22 Global Viral Gastroenteritis Market Outlook, By Chemotherapy Drugs (2021-2030) ($MN)
  • Table 23 Global Viral Gastroenteritis Market Outlook, By Other Drugs (2021-2030) ($MN)
  • Table 24 Global Viral Gastroenteritis Market Outlook, By Dosage (2021-2030) ($MN)
  • Table 25 Global Viral Gastroenteritis Market Outlook, By Tablet (2021-2030) ($MN)
  • Table 26 Global Viral Gastroenteritis Market Outlook, By Injection (2021-2030) ($MN)
  • Table 27 Global Viral Gastroenteritis Market Outlook, By Other Dosages (2021-2030) ($MN)
  • Table 28 Global Viral Gastroenteritis Market Outlook, By Indication (2021-2030) ($MN)
  • Table 29 Global Viral Gastroenteritis Market Outlook, By Watery Diarrhea (2021-2030) ($MN)
  • Table 30 Global Viral Gastroenteritis Market Outlook, By Vomiting (2021-2030) ($MN)
  • Table 31 Global Viral Gastroenteritis Market Outlook, By Abdominal Pain and Cramps (2021-2030) ($MN)
  • Table 32 Global Viral Gastroenteritis Market Outlook, By Dizziness (2021-2030) ($MN)
  • Table 33 Global Viral Gastroenteritis Market Outlook, By Diarrhea (2021-2030) ($MN)
  • Table 34 Global Viral Gastroenteritis Market Outlook, By Nausea (2021-2030) ($MN)
  • Table 35 Global Viral Gastroenteritis Market Outlook, By Vomiting (2021-2030) ($MN)
  • Table 36 Global Viral Gastroenteritis Market Outlook, By Headache (2021-2030) ($MN)
  • Table 37 Global Viral Gastroenteritis Market Outlook, By Chills (2021-2030) ($MN)
  • Table 38 Global Viral Gastroenteritis Market Outlook, By Loss of Appetite (2021-2030) ($MN)
  • Table 39 Global Viral Gastroenteritis Market Outlook, By Fever (2021-2030) ($MN)
  • Table 40 Global Viral Gastroenteritis Market Outlook, By Joint Stiffness (2021-2030) ($MN)
  • Table 41 Global Viral Gastroenteritis Market Outlook, By Sweating (2021-2030) ($MN)
  • Table 42 Global Viral Gastroenteritis Market Outlook, By Muscle Pain (2021-2030) ($MN)
  • Table 43 Global Viral Gastroenteritis Market Outlook, By Weight Loss (2021-2030) ($MN)
  • Table 44 Global Viral Gastroenteritis Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 45 Global Viral Gastroenteritis Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 46 Global Viral Gastroenteritis Market Outlook, By Oral (2021-2030) ($MN)
  • Table 47 Global Viral Gastroenteritis Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 48 Global Viral Gastroenteritis Market Outlook, By Others (2021-2030) ($MN)
  • Table 49 Global Viral Gastroenteritis Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 50 Global Viral Gastroenteritis Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 51 Global Viral Gastroenteritis Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 52 Global Viral Gastroenteritis Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 53 Global Viral Gastroenteritis Market Outlook, By End User (2021-2030) ($MN)
  • Table 54 Global Viral Gastroenteritis Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 55 Global Viral Gastroenteritis Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
  • Table 56 Global Viral Gastroenteritis Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.